Logo Prima Biomed


Welcome to the Newsroom

13 October 2016

Prima to Present at 2016 Society for Immunotherapy of Cancer Conference


SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima”) announces that the nsubmission titled "LAG-3Ig (IMP321) in combination with anti-PD-1 therapy" has been accepted for a presentation at the Society for Immunotherapy of Cancer (SITC)'s New Cancer Immunotherapy Agents in Development program.

(...)